Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for nine companies, including Hemei Pharmaceutical, regarding their overseas listing applications [1] - Hemei Pharmaceutical is required to clarify its previous A-share listing guidance and whether it plans to continue with the A-share listing process [1] - The company was founded in 2002 and focuses on discovering and developing small molecule drugs for autoimmune diseases and tumors, positioning itself at the forefront of the industry [2] Group 2 - As of May 21, 2025, Hemei Pharmaceutical has developed seven small molecule drug candidates targeting unmet needs in autoimmune and tumor diseases, with four candidates in clinical trials or NDA stages for twelve indications [2] - The core product, Mufemilast, is a novel small molecule PDE4B protein expression blocker and PDE4 inhibitor, showing potential for treating a wide range of autoimmune diseases [2] - According to Frost & Sullivan, Mufemilast may be a first-in-class drug with dual mechanisms of action, blocking PDE4B protein expression and inhibiting PDE4 activity [2]
和美药业拟港股上市 中国证监会要求补充说明前期进行A股上市辅导备案的详细情况等
Zhi Tong Cai Jing·2025-08-01 14:01